Charles Schwab
RNTX

Charles Schwab’s Rein Therapeutics RNTX Stock Holding History

Charles Schwab’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,370
Closed -$35K – 3551
2021
Q2 		$35K Hold
1,370
– – ﹤0.01% 3404
2021
Q1 		$40K Buy
+1,370
New +$46.9K ﹤0.01% 3464
2017
Q4 		– Sell
-615
Closed -$165K – 3063
2017
Q3 		$165K Buy
+615
New +$154K ﹤0.01% 3035

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's RNTX Position: Q3 2021 in Review

Charles Schwab sold out of Rein Therapeutics (RNTX) in Q3 2021, closing a stake of 1,370 shares — an estimated $35K sold.

Charles Schwab first reported a position in RNTX in Q3 2017 and held it in 3 quarters. The position peaked at $165K in Q3 2017. 43 funds tracked by Wall St. Rank hold RNTX as of Q3 2021.

  • Charles Schwab reported no remaining Rein Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Charles Schwab sold 1,370 Rein Therapeutics shares in Q3 2021, an estimated $35K.
  • Charles Schwab first reported a position in Rein Therapeutics in Q3 2017 and held it in 3 quarters.
  • Charles Schwab's Rein Therapeutics position peaked at $165K in Q3 2017.
  • 43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2021.

Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.